Kidney transplant rejection

8 trials 2 recruiting MedDRA PT
8 Registered trials
2 Recruiting
5 Unique sponsors
11 Unique IMPs
8 Commercial trials
Drug classes (ATC)
L Oncology (ATC L) 6
— ATC code not specified 1
H Endocrinology (ATC H) 1
B Haematology (ATC B) 1
Mechanism of action (INN-stem analysis)
Unknown / small molecule 5 substances
Monoclonal antibody (immune) 1 substance
Calcineurin inhibitor 1 substance
Immunosuppressant 1 substance
Corticosteroid 1 substance
Monoclonal antibody 1 substance
Supportive / diluent 1 substance
Phase III: 3 Phase II/III: 1 Phase II: 3 Phase I (Other): 1

Filter these 8 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 8 trials

Phase III

3 trials
  • Biogen Idec Research Limited Commercial
    FELZARTAMAB; SODIUM CHLORIDE
    2024-519095-66-00 5 countries 2025 n=49 Orphan
    Ended
  • Hansa Biopharma AB Commercial
    IMLIFIDASE
    2022-502727-21-00 8 countries 2023 n=126 Orphan
    Ended
  • Hansa Biopharma AB Commercial
    IMLIFIDASE
    2024-511810-18-00 10 countries 2022 n=144 Orphan
    Ended

Phase II/III

1 trial
  • Sanofi-Aventis Recherche & Developpement Commercial
    FREXALIMAB; TACROLIMUS
    2025-521521-33-00 12 countries 2026 n=269
    Recruiting

Phase II

3 trials
  • Eledon Pharmaceuticals Inc. Commercial
    ANTITHYMOCYTE IMMUNOGLOBULIN; AT-1501; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; PREDNISOLONE; TACROLIMUS; TEGOPRUBART
    2023-503336-41-00 3 countries 2023 n=101
    Ended
  • Eledon Pharmaceuticals Inc. Commercial
    AT-1501; TACROLIMUS
    2023-503337-21-00 3 countries 2025 n=30
    Ended
  • Hansa Biopharma AB Commercial
    IMLIFIDASE
    2022-500230-28-00 4 countries 2023 n=8 Orphan
    Recruiting

Phase I (Other)

1 trial
  • Nucleus Medical GmbH Commercial
    IMP not specified
    2025-525076-29-00 1 country 2026 n=6
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Hansa Biopharma AB Commercial 3 Phase II, Phase III 1
Eledon Pharmaceuticals Inc. Commercial 2 Phase II 0
Sanofi-Aventis Recherche & Developpement Commercial 1 Phase II/III 1
Nucleus Medical GmbH Commercial 1 Phase I (Other) 0
Biogen Idec Research Limited Commercial 1 Phase III 0
New trials by year
2022
1
2023
3
2025
2
2026
2
← All indication landscapes